ДИУРЕТИКИ КАК АНТИГИПЕРТЕНЗИВНЫЕ ПРЕПАРАТЫ: ДЕЙСТВИТЕЛЬНО ЛИ НЕОБХОДИМЫ ПОИСКИ ЛУЧШЕГО В КЛАССЕ?


Цитировать

Полный текст

Аннотация

В последние годы активно обсуждаются возможные преимущества отдельных тиазидных и тиазидоподобных диуретиков с точки зрения эффективности и меньшего числа нежелательных явлений. В статье представлены согласованные и спорные позиции, касающиеся выбора тиазидных и тиазидоподобных диуретиков для лечения артериальной гипертензии.

Об авторах

V Fomin

Виктор Викторович Фомин

Кафедра терапии и профболезней ММА им. И.М. Сеченова, Москва

Кафедра терапии и профболезней ММА им. И.М. Сеченова, Москва

Список литературы

  1. Российское медицинское общество по артериальной гипертонии - Всероссийское научное общество кардиологов. Диагностика и лечение артериальной гипертензии. Российские рекомендации (третий пересмотр.). М., 2008.
  2. Dahlof B, Sever PS, Poulter NR, et al.; ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366:895-906.
  3. Reungjui S, Pratipanawatr T, Johnson RJ, et al. Do thiazides worsen metabolic syndrome and renal disease? The pivotal roles for hyperuricemia and hypokalemia. Curr Opin Nephrol Hypertens 2008;17(5):470-76.
  4. Lindholm LH, Carlberg B, Samuelsson O. Should beta-blockers remain first-choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366:1545-53.
  5. Chalmers J, MacMahon S, Manchia G, et al. 1999 World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens 1999;21(5-6):1009-60.
  6. Shafi T, Appel LJ, Miller ER, et al. Changes in serum potassium mediates thiazide-induced diabetes. Hypertension 2008;52:1022-29.
  7. Kostis JB, Wilson AC, Freudenberger RS, et al. Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005;95:29-35.
  8. The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium-channel blocker vs diuretic: The Antihypertensive an Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981-97.
  9. Barzilay JI, Davis BR, Cutler JA, et al. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006;166:2191-201.
  10. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium and the development of diabetes. A quantative review. Hypertension 2006;48:219-24.
  11. Чазова И.Е., Ратова Л.Г. Комбинированная терапия артериальной гипертонии // Сердце. 2005. Т. 4(3). С. 120-126.
  12. Sowers JR, Neuten JM, Saunders E, et al. Antihypertnensive efficacy of irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens 2006;8:470-80.
  13. Derosa G, Ferrari I, Cicero AF. Irbesartan and hydrochlorothiazide association in the treatment of hypertension. Curr Vasc Pharmacol 2009;7(2):120-36.
  14. Patel A.; ADVANCE Collaborative Group, MacMahon S., Chalmers J. et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370(9590):829-40.
  15. Shah SU, Anhjum S, Littler WA. Use of diuretics in cardiovascular disease: (2) hypertension. Postgrad Med J 2004;80:271-76.
  16. Hypertension Detection and Follow-up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. III. Reduction in stroke incidence among persons with high blood pressure. JAMA 1982;247(5):633-38.
  17. Kreeft JH, Langlois S, Ogilvie RI. Comparative trial of indapamide and hydrochlorothiazide in essential hypertension, with forearm plethysmography. J Cardiovasc Pharmacol 1984;6(4):622-26.
  18. Spence JD, Huff M, Barnett PA. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. Can J Clin Pharmacol 2000;7(1):32-37.
  19. Elliott WJ, Weber RR, Murphy MB. A double-blind, randomized, placebo-controlled comparison of the metabolic effects of low-dose hydrochlorothiazide and indapamide. J Clin Pharmacol 1991;31(8):751-57.
  20. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003;17(5-6):397-414.
  21. Gurwitz JH, Kalish SC, Bohn RL, et al. Thiazide diuretics and the initiation of anti-gout therapy. J Clin Epidemiol 1997;50(8):953-59.
  22. Inaba M, Noguchi Y, Yamamoto T, et al. Effects of a low dose of indapamide, a diuretic, given daily or every-other-day on blood pressure and metabolic parameters. Hypertens Res.2004;27(3):141-45.
  23. Yamada H, Mishiro Y, Kusunose K, et al. Effects of additional administration of low-dose indapamide on patients with hypertension treated with angiotensin II receptor blocker. J Cardiovasc Pharmacol Ther 2010;15(2):145-50.
  24. Achimastos A, Liberopoulos E, Nikas S, et al. The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide. Curr Med Res Opin 2002;18(2):59-63.
  25. Недогода С.В., Барыкина И.Н., Брель У.А. и др. Возможность коррекции Равелом СР факторов риска при артериальной гипертензии на фоне ожирения // Системные гипертензии. 2007. № 1. С. 14-18.
  26. Reisin E, Weir MR, Falkner B, et al. Lisinopril versus hydrochlorothiazide in obese hypertensive patients: a multicenter placebo-controlled trial. Treatment in Obese Patients With Hypertension (TROPHY) Study Group. Hypertension 1997;30(1 Pt. 1):140-45.
  27. Emeriau JP, Knauf H, Pujadas JO, et al. A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study. J Hypertens 2001;19(2):343-50.
  28. Luccioni R, Sever PS, Di Perri T, et al. An equivalence study of the safety and efficacy of a fixed-dose combination of perindopril with indapamide versus fixed-dose combinations of captopril with hydrochlorothiazide and enalapril with hydrochlorothiazide in the treatment of hypertension. J Hypertens 1995;13(12 Pt. 2):1847-51.
  29. Carter BL, Ernst ME, Cohen JD. hydrochlorothiazide versus chlorothalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9.
  30. Sumiye L, Vivian AS, Frisof KB, et al. Potassium loss associated with hydrochlorothiazide versus chlorthalidone. Clin Ther 1981;4(4):308-20.
  31. Izzo JL, Neutel JM, Silfani T, et al. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens (Greenwich). 2007;9(1):45-48.
  32. Keyes JW, Breneman GM, Alvarez H. Chlorothiazide and hydrochlorothiazide in the treatment of congestive heart failure. Int Rec Med Gen Pract Clin 1959;172(8):454-60.
  33. Dormans TP, Gerlag PG. Combination of high-dose furosemide and hydrochlorothiazide in the treatment of refractory congestive heart failure. Eur Heart J 1996;17(12):1867-74.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах